Pfizer Inc.
Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer

Last updated:

Abstract:

This invention relates to a method of treating non-small cell lung cancer by administering an EGFR T790M inhibitor in combination with a CDK inhibitor to a patient in need thereof.

Status:
Application
Type:

Utility

Filling date:

7 Nov 2017

Issue date:

12 Sep 2019